Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86,732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making.
Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L. Taylor PC, et al. Among authors: chen c. Patient Prefer Adherence. 2020 Jan 20;14:119-131. doi: 10.2147/PPA.S220714. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32021123 Free PMC article.
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Cohen SB, Greenberg JD, Harnett J, Madsen A, Smith TW, Gruben D, Zhang R, Lukic T, Woolcott J, Dandreo KJ, Litman HJ, Blachley T, Lenihan A, Chen C, Rivas JL, Dougados M. Cohen SB, et al. Among authors: chen c. Adv Ther. 2021 Jan;38(1):226-248. doi: 10.1007/s12325-020-01501-z. Epub 2020 Oct 9. Adv Ther. 2021. PMID: 33034006 Free PMC article.
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
Tanaka Y, Sugiyama N, Toyoizumi S, Lukic T, Lamba M, Zhang R, Chen C, Stock T, Valdez H, Mojcik C, Fan H, Deng C, Yuasa H. Tanaka Y, et al. Among authors: chen c. Rheumatology (Oxford). 2019 Jan 1;58(1):70-79. doi: 10.1093/rheumatology/key250. Rheumatology (Oxford). 2019. PMID: 30137547 Free PMC article. Clinical Trial.
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Lee EB, Yamanaka H, Liu Y, Tsai WC, Chen C, Kwok K, Yoo HJ, Llamado LJ, Wang L, Luo Y, Sugiyama N, Tanaka Y. Lee EB, et al. Among authors: chen c. Int J Rheum Dis. 2019 Jun;22(6):1094-1106. doi: 10.1111/1756-185X.13516. Epub 2019 Mar 22. Int J Rheum Dis. 2019. PMID: 30900375 Free PMC article.
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Cohen SB, et al. Among authors: chen c. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. RMD Open. 2020. PMID: 33127856 Free PMC article. Clinical Trial.
86,732 results
You have reached the last available page of results. Please see the User Guide for more information.